OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Gandara on Online Treatment Decision Tool for Lung Cancer

September 27th 2018

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), a 2017 Giant of Cancer Care® in Lung Cancer, discusses the idea for an online treatment decision tool for lung cancer.

Dr. Paulson Discusses Unmet Needs in the Treatment of NETs

September 27th 2018

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses unmet needs in the treatment of patients with neuroendocrine tumors.

Dr. Smith Discusses Novel CAR T-Cell Therapies for Myeloma

September 27th 2018

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses novel chimeric antigen receptor (CAR) T-cell therapies in development for the treatment of patients with multiple myeloma.

Dr. Tolaney on Recent Advances in HR-Positive Breast Cancer

September 27th 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses recent advances in the treatment of patients with hormone receptor-positive breast cancer.

Dr. Wang on Managing AEs Related to BTK Inhibitors

September 27th 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses how to manage adverse events related to BTK inhibitors in the treatment of mantle cell lymphoma.

Dr. Michaelis Discusses the JAK2 Mutation in MPNs

September 26th 2018

Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses implications for the JAK2 mutation in patients with myeloproliferative neoplasms.

Dr. Heifetz Discusses Rural Oncology Care

September 26th 2018

Laurence J. Heifetz, MD, medical director, Gene Upshaw Memorial Tahoe Forest Cancer Center, discusses rural oncology care.

Dr. Llovet on Combination Therapy in HCC

September 26th 2018

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential of combination therapy in hepatocellular carcinoma.

Dr. Yang on the Future of Acute Myeloid Leukemia

September 26th 2018

Jay Yang, MD, oncologist, Barbara Ann Karmanos Cancer Institute, discusses the future of acute myeloid leukemia (AML).

Dr. Shadman on the Future of Venetoclax in CLL

September 26th 2018

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, discusses the future of venetoclax (Venclexta) in the treatment of chronic lymphocytic leukemia (CLL).

Dr. Cortes Discusses Quizartinib in AML

September 26th 2018

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses quizartinib for the treatment of patients with acute myeloid leukemia.

Dr. Mohile on Implementing Geriatric Assessment into Cancer Care

September 26th 2018

Supriya Gupta Mohile, MD, MS, professor of medicine and surgery, James Wilmot Cancer Institute, director, Geriatric Oncology Clinic, University of Rochester, discusses implementing geriatric assessments into cancer care.

Dr. Pennell on the Cost Effectiveness of NGS in NSCLC

September 26th 2018

Nathan A. Pennell, MD, PhD, director, Lung Cancer Medical Oncology Program, Cleveland Clinic Taussig Cancer Institute, discusses the cost-effectiveness of next-generation sequencing for patients with metastatic non–small cell lung cancer.

Dr. Zonder on Induction Therapy in Newly Diagnosed Multiple Myeloma

September 26th 2018

Jeffrey Zonder, MD, associate professor of oncology and medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses induction therapy in the treatment of patients with newly diagnosed multiple myeloma.

Dr. Meeks on the Genomics of Bladder Cancer

September 26th 2018

Joshua Meeks, MD, PhD, assistant professor of urology, biochemistry, and molecular genetics, Northwestern University Feinberg School of Medicine, section chief of robotic surgery, Jesse Brown VA Medical Center, discusses the genomics of bladder cancer.

Dr. Uberti on Transplant in Myelodysplastic Syndrome

September 26th 2018

Joseph Uberti, MD, PhD, division head, BMT, Leukemia & Lymphoma, professor of medicine, Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses the use of transplant in myelodysplastic syndrome (MDS).

Dr. Villanueva on Challenges For Liquid Biopsies in HCC

September 25th 2018

Augusto Villanueva, MD, PhD, assistant professor, Icahn School of Medicine, discusses remaining challenges with liquid biopsies in hepatocellular carcinoma.

Dr. Burgess on PARP Resistance in Ovarian Cancer

September 25th 2018

Brian T. Burgess, DO, first-year fellow, University of Kentucky Markey Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.

Dr. Oxnard on Potential of Genome Wide Sequencing With cfDNA

September 25th 2018

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the potential impact of implementing cell-free DNA tests as a method to detect signs of early stage cancer.

Dr. Kreitman on the Prognosis of Hairy Cell Leukemia

September 25th 2018

Robert J. Kreitman, MD, chief, Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, discusses the prognosis for patients diagnosed with hairy cell leukemia.